You are here: Industry Insights > Baricitinib

News List

Common Treatments for Rheumatoid Arthritis David Orchard-Webb
July 01, 2024
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, including the skin, eyes, lungs, heart, and blood vessels.
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation worldpharmanews
August 04, 2021
Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who ...
Lilly-Incyte’s baricitinib lowers mortality in Phase III Covid-19 trial pharmaceutical-technology
August 04, 2021
Eli Lilly and Incyte have reported new data from Phase III COV-BARRIER sub-study, where baricitinib lowered mortality risk in Covid-19 patients receiving mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
FDA Broadens Existing Emergency Use of Lilly and Incyte's Baricitinib in Patients Hospitalized with COVID-19 Requiring Oxygen drugs
August 02, 2021
Eli Lilly and Company and Incyte announced today FDA has broadened the Emergency Use Authorization for baricitinib to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir.
FDA Authorizes New Standalone Treatment for COVID-19 americanpharmaceuticalreview
July 30, 2021
The U.S. FDA revised the Emergency Use Authorization (EUA) for baricitinib (sold under the brand name Olumiant) now authorizing baricitinib alone for the treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older ...
FDA expands EUA for Lilly-Incyte’s baricitinib as Covid-19 monotherapy pharmaceutical-technology
July 30, 2021
The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for Eli Lilly and Incyte’s drug, baricitinib, for Covid-19 treatment with or without remdesivir.
Bajaj Healthcare applies to Indian patent office for compulsory licence for Baricitinib expresspharma
June 30, 2021
Considering Bajaj Healthcare's manufacturing capabilities and strong in-house R&D team, we can produce Baricitinib at very competitive and affordable prices in India, said Anil Jain, Joint MD, Bajaj Healthcare.
Mankind Pharma partners with BDR Pharma to distribute Baricitinib in India expresspharma
June 25, 2021
BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from Eli Lilly and Company, and Mankind Pharma will be distributing the same.
BDR Pharma signs voluntary licensing agreement with Lilly for baricitinib expresspharma
May 20, 2021
Lilly had recently announced seven other voluntary license agreements with major drug manufacturers in India for the production of baricitinib.
Lilly signs voluntary licensing agreement with Natco for baricitinib expresspharma
May 18, 2021
Lilly had also signed voluntary license agreements with Cipla, Lupin, Sun Pharma, Dr Reddy’s, MSN Labs and Torrent Pharma.

Previous page 1 2 3 4 5 Next page